Download the Full Event Guide

Join us virtually this June (8-10), as the trailblazers of TCR therapeutics, from the likes of Immunocore, Immatics and Abbvie come together to drive the clinical development of safe and efficacious TCR therapies.

Front Page Brochure

 

Snapshot of Top 5 Discussions:

  1. Explore the importance of binding affinity and T cell exhaustion with 3T Bioscience and University of Washington to supercharge your knowledge of fundamental TCR biology
  2. Drive novel target discovery to accelerate the characterization and validation of identified targets with Enara Bio, Tscan and Erasmus MS Cancer Institute
  3. Overcome the issue of toxicity and off-target/on-target effects for the development of a safe TCR product with 3T Bioscience, and Anocca
  4. Accelerate development of soluble TCR-T’s for T cell activation with Abbvie, Eureka Therapeutics and Memorial Sloan Kettering Cancer Center
  5. Maximize the potential of TCR therapies with Triumvira Immunologics and Medigene by overcoming the solid tumor microenvironment